MedTrace Logo

Developing Artificial Intelligence-based Algorism to Predict Side Effects and Symptoms From Chemotherapy

NCT05937477 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2023-07-21

No results posted yet for this study

Summary

In this study, the investigators obtain wearable disease based biomarkers from patients diagnosed with cancer and undergoing chemotherapy, and simultaneously measure patient self-reported adverse events through an app to evaluate chemotherapy completion rates, emergency room visits, and frequency of CTCAE adverse events.

The investigators will develop an artificial intelligence-based algorism that can predict patients' side effects based on biomarkers alone.

Conditions

Interventions

OTHER

Fitbit smartwatch

Patients wear the wearable to check their biomarkers and use the application to assess their quality of life and side effects at one-week intervals.

Sponsors & Collaborators

  • Sehhoon Park

    lead OTHER

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-08
Primary Completion
2025-12-31
Completion
2026-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05937477 on ClinicalTrials.gov